Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 14,891,000 | 13,565,000 | 12,938,000 | 12,679,000 | 12,024,000 |
| Cost of Goods | 2,725,000 | 3,081,000 | 2,183,000 | 2,218,000 | 2,308,000 |
| Gross Profit | 12,166,000 | 10,484,000 | 10,755,000 | 10,461,000 | 9,716,000 |
| Operating Expenses | 10,130,000 | 8,378,000 | 8,009,000 | 7,346,000 | 8,482,000 |
| Operating Income | 2,036,000 | 2,106,000 | 2,746,000 | 3,115,000 | 1,234,000 |
| Interest Expense | 429,000 | 457,000 | 443,000 | 413,000 | 438,000 |
| Other Income | 59,000 | 179,000 | 94,000 | 98,000 | 101,000 |
| Pre-tax Income | 1,666,000 | 1,828,000 | 2,397,000 | 2,800,000 | 897,000 |
| Income Tax | 166,000 | 395,000 | 469,000 | 620,000 | -62,000 |
| Net Income Continuous | 1,500,000 | 1,433,000 | 1,928,000 | 2,180,000 | 959,000 |
| Minority Interests | 1,000 | 4,000 | 1,000 | N/A | N/A |
| Net Income | $1,499,000 | $1,429,000 | $1,927,000 | $2,180,000 | $959,000 |
| EPS Basic Total Ops | -1.30 | 0.92 | 1.24 | 1.41 | 0.62 |
| EPS Basic Continuous Ops | -1.30 | 0.92 | 1.24 | 1.41 | 0.62 |
| EPS Diluted Total Ops | -1.30 | 0.91 | 1.24 | 1.40 | 0.60 |
| EPS Diluted Continuous Ops | -1.30 | 0.92 | 1.24 | 1.40 | 0.61 |
| EPS Diluted Before Non-Recurring Items | 2.10 | 2.08 | 1.98 | N/A | N/A |
| EBITDA(a) | $4,373,000 | $3,923,000 | $4,025,000 | $4,370,000 | $2,561,000 |